Washington [US], September 2 (ANI): Researchers have published results that show encouraging therapeutic options for patients with blood cancer and multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific antibodies are a type of antibody that can bind to two different antigens at the same time -- they are meant to enhance the immune system's destruction of tumour cells.
\
\
